Press Releases
-
Feb 11, 2021- Two-fold increase (29% to 63%) in disease control rate at 12 weeks (the trial's primary efficacy endpoint) seen in patients receiving onvansertib for 14 days vs. 5 days in a 21-day cycle
\
Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need